Report warns of crisis due to decline in generic drugs in Europe

Teva Pharmaceuticals, the world’s largest generic drug maker, found in its research that the number of generic drugs withdrawn from the market jumped 12%, while new generic drug launches declined by an average of 3% annually. It is claimed that there is.

The magazine points out that in 2012 there were 40,280 different generic products in Europe. However, just 10 years later, this number plummeted to 29,836 generic drugs, a massive 26% decrease.

According to the company, generic drugs that contain the same active ingredients as previously patent-protected drugs account for 67% of all drugs sold. In most cases, the patent term lasts 20 years, but the European Union allows an additional 5 years of patent recovery under certain conditions.

However, generic drugs have the advantage of more competitive pricing, making them popular among consumers and retailers.

Teva’s study ‘Health Check for Critical Medicines’ cites antimicrobial resistance as a growing health problem across Europe, warning of a growing health problem across Europe, with the region now using 31% more antibiotic medicines than they did 10 years ago. It added that antibiotic syrups for children have also significantly decreased by 21%.

Additionally, the report found that while the Kobedo pandemic has reduced life expectancy on the continent by 0.7 years, cancer rates have increased significantly, reaching 202 deaths per 100,000 people in 2021 compared to 191 in 2019. It claims to have recorded the death. The number of generic cancer drugs has decreased. 38% during the period.

The report recommends three key actions: A framework for better incentives for innovation to encourage the development of complex treatments. Legal clarification on generic drug launches to increase access and diversity. Protect mature essential medicines through sustainable market practices, improved procurement, and optimized regulatory frameworks.